Abstract Tumor phenotype and therapeutic vulnerability are shaped by dynamic transcriptional states that are not captured by genetic profiling alone and are difficult to monitor longitudinally. Existing plasma-based approaches have largely been developed using samples with high circulating tumor DNA fractions, evaluate...
M. Freedman, G. Gulati, D. Vasseur et al.· Research Square· 0 citations
The combination of azenosertib and gemcitabine was associated with substantial myelosuppression in patients with metastatic PDAC previously treated with FOLFIRINOX, limiting further clinical evaluation of this dosing strategy.
B. Huffman, Haeseong Park, Nadine A. Jackson et al.· Cancer Research· 0 citations
It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.
Sarah Kang, M. Parikh, Leontios Pappas et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage with limited treatment options. Patient-derived organoids (PDOs) can model tumors, identify determinants of therapeutic response, and support precision medicine. In the multi-institutional PASS-01 trial of metastatic PDAC, biopsies f...
A. Habowski, Fatim M. Kouassi, James A. Rouse et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
